Vemurafenib resistance reprograms melanoma cells towards glutamine dependence

BACKGROUND: (V600)BRAF mutations drive approximately 50% of metastatic melanoma which can be therapeutically targeted by BRAF inhibitors (BRAFi) and, based on resistance mechanisms, the combination of BRAF and MEK inhibitors (BRAFi + MEKi). Although the combination therapy has been shown to provide...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Transl Med
Autors principals: Hernandez-Davies, Jenny E, Tran, Thai Q, Reid, Michael A, Rosales, Kimberly R, Lowman, Xazmin H, Pan, Min, Moriceau, Gatien, Yang, Ying, Wu, Jun, Lo, Roger S, Kong, Mei
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4490757/
https://ncbi.nlm.nih.gov/pubmed/26139106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0581-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars